These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 3738857

  • 21. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE.
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [Abstract] [Full Text] [Related]

  • 22. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate.
    Hampton KK, Preston FE, Lowe GD, Walker ID, Sampson B.
    Br J Haematol; 1993 Jun; 84(2):279-84. PubMed ID: 8398831
    [Abstract] [Full Text] [Related]

  • 23. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor.
    Mizon P, Goudemand J, Jude B, Marey A.
    Ann Hematol; 1992 Jun; 64(6):309-11. PubMed ID: 1637888
    [Abstract] [Full Text] [Related]

  • 24. Abnormalities in thrombin-antithrombin pathway in AL amyloidosis.
    Gamba G, Montani N, Anesi E, Palladini G, Lorenzutti F, Perfetti V, Merlini G.
    Amyloid; 1999 Dec; 6(4):273-7. PubMed ID: 10611948
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C, Menart C, Attali O, Petit PY, Lienhart A, Dechavanne M, Ingerslev J.
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [Abstract] [Full Text] [Related]

  • 26. [Antithrombin III concentrate use in patients with cirrhosis with coagulation disorders].
    Ribeiro AA, Lourenço DM, Toledo CF, Noguti MA, Borges DR.
    Rev Assoc Med Bras (1992); 1997 Mar; 43(3):189-94. PubMed ID: 9497544
    [Abstract] [Full Text] [Related]

  • 27. Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery.
    Bardin JM, Sultan Y.
    Transfusion; 1990 Jun; 30(5):441-3. PubMed ID: 2360238
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Treatment of congenital antithrombin III deficiency with concentrates.
    Mannucci PM, Boyer C, Wolf M, Tripodi A, Larrieu MJ.
    Br J Haematol; 1982 Mar; 50(3):531-5. PubMed ID: 7066204
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Antithrombin III. Physiologic, physiopathologic and laboratory aspects].
    de Sousa JC, Ferreira R, Carriço F, Nunes V, Geraldes MJ, Parreira F, Ribeiro C.
    Rev Port Cardiol; 1991 Sep; 10(9):693-9. PubMed ID: 1747261
    [Abstract] [Full Text] [Related]

  • 34. Metabolism of antithrombin III in cirrhosis and carcinoma of the liver.
    Chan V, Lai CL, Chan TK.
    Clin Sci (Lond); 1981 Jun; 60(6):681-8. PubMed ID: 6265140
    [Abstract] [Full Text] [Related]

  • 35. Safety of recombinant coagulation factors in treating hemophilia.
    Morfini M, Rapisarda CAP.
    Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M.
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.